Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder, Neurogenic
Conditions
Urinary Bladder, Neurogenic
Trial Timeline
Jul 2, 2012 → Feb 13, 2020
NCT ID
NCT01557244About Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mg
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mg is a phase 3 stage product being developed by Pfizer for Urinary Bladder, Neurogenic. The current trial status is completed. This product is registered under clinical trial identifier NCT01557244. Target conditions include Urinary Bladder, Neurogenic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01557244 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Bladder, Neurogenic